Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlle...
Medite Cancer Diagnostics reported revenue of $6.81 million for fiscal year 2017, down 26.3% from fiscal year 2016, and net income of -$6.90 million. In Q3 2018 (the quarter ended September 30, 2018) revenue was $2.39 million, up 42.0% from a year before. Its market capitalization was $8,672 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2017; market data as of October 8, 2026.
No profile data available.